A Phase 1 interventional study of Single Dose Group: Belimumab IV 240 mg and Single Dose Group: Belimumab SC 2 x 120 mg in Healthy, sponsored by Human Genome Sciences Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-07.
Sponsored by Human Genome Sciences Inc. (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 16th largest by enrollment, is one of 3 that started in 2011, is one of 7 in phase 1, and was the 12th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Nanjing University School of Medicine · Sites in China
Ages 14–65
National University Hospital, Singapore · Sites in Singapore
Ages 21–70
First Affiliated Hospital Xi'an Jiaotong University
Ages 18+
By country, each count listing its studies:
belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 118 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 81 across the 36 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Human Genome Sciences Inc., one of the names counted as GlaxoSmithKline. Under that name alone:
Human Genome Sciences Inc. is the lead sponsor of 23 studies on the registry; none are open to participants now.
43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 26 (72%) have results posted.
Among the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, this one is the 16th largest by enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2011, is one of 14 in phase 1, and was the 15th registered.
GlaxoSmithKline’s Lupus Erythematosus, Systemic studies by the year they started, since 2002.
2 of the studies testing belimumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340463Nanjing University School of MedicineThe Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | 2027-06 |
| NCT06411249GlaxoSmithKlineA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | 2027-06-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, from their registry updates:
Among GlaxoSmithKline’s 43 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure the amount of belimumab in the blood when given as an injection under the skin (subcutaneously; SC) and to evaluate the safety and tolerability of multiple injections under the skin in healthy subjects.
This study is designed to evaluate the absolute bioavailability, pharmacokinetics, tolerability, and safety of a single dose (groups 1-4) or multiple doses (groups 5-6) of belimumab administered subcutaneously (SC) to healthy subjects.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Single Dose Group: Belimumab IV 240 mg
Biological: Single Dose Group: Belimumab SC 2 x 120 mg
Biological: Single Dose Group: Belimumab SC 1 x 240 mg
Biological: Single Dose Group: Belimumab SC 1 x 200 mg
Biological: Multiple Dose Group: Belimumab SC 2 x 120 mg weekly
Biological: Multiple Dose Group: Belimumab SC 1 x 200 mg weekly
Belimumab IV 240 mg administered on Day 0
Also known as: BENLYSTA™
Belimumab SC 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Day 0
Also known as: BENLYSTA™
Belimumab SC 240 mg x 1 injection on Day 0
Also known as: BENLYSTA™
Belimumab SC 200 mg x 1 injection on Day 0
Also known as: BENLYSTA™
Belimumab 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Days 0, 7, 14, and 21
Also known as: BENLYSTA™
Belimumab 200 mg x 1 injection administered on Days 0, 7, 14, and 21
Also known as: BENLYSTA™
Time to Reach Maximum Serum Drug Concentration (Tmax) Following a Single Dose of Belimumab Given as Intravenous Infusion (IV) or Subcutaneous Injection (SC)
Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 42, 56, and 70
Maximum Serum Drug Concentration (Cmax) Following a Single Dose of Belimumab Given as IV or SC
Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 42, 56, and 70
Area Under the Serum Drug Concentration-time Curve From Time 0 to Infinite Time (AUC0-∞) Following a Single Dose of Belimumab Given as IV or SC
AUC (0-∞) = Area under the serum drug concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-last) plus C (last)/λz. C (last) is the last measurable concentration. λz was determined by linear regression (r2 ≥ 0.8) with uniform weighting of all data in the terminal linear portion of the log-transformed drug concentration-time profile.
Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 42, 56, and 70
Terminal Elimination Half-life (t1/2,Term) Following a Single Dose of Belimumab Given as IV or SC
Terminal elimination half-life is the time measured for the serum drug concentration of belimumab to decrease by one half.
Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 42, 56, and 70
Absolute Bioavailability of a Single Dose of Belimumab Given as IV or SC
Bioavailability (F) is a measurement of the rate and extent to which a drug reaches the systemic circulation. The bioavailability of belimumab administered by IV is compared to the bioavailability of belimumab administered via single-SC injection.
Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 10, 14, 21, 28, 42, 56, and 70
Time to Reach Maximum Serum Drug Concentration (Tmax) Following Weekly (x 4) SC Injections of Belimumab
Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 14, 21, 22, 23, 24, 25, 26, 27, 28, 31, 35, 42, 49, 63, 77, 91, and 119
Maximum Serum Drug Concentration (Cmax) Following Weekly (x 4) SC Injections of Belimumab
Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 14, 21, 22, 23, 24, 25, 26, 27, 28, 31, 35, 42, 49, 63, 77, 91, and 119
Area Under the Serum Drug Concentration-time Curve From Time 0 to Infinite Time (AUC0-∞) Following Weekly (x 4) SC Injections of Belimumab
AUC (0-∞) = Area under the serum drug concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-last) plus C (last)/λz. C (last) is the last measurable concentration. λz was determined by linear regression (r2 ≥ 0.8) with uniform weighting of all data in the terminal linear portion of the log-transformed drug concentration-time profile.
Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 14, 21, 22, 23, 24, 25, 26, 27, 28, 31, 35, 42, 49, 63, 77, 91, and 119
Terminal Elimination Half-life (t1/2,Term) Following Weekly (x 4) SC Injections of Belimumab
Terminal elimination half-life is the time measured for the serum drug concentration of belimumab to decrease by one half.
Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 14, 21, 22, 23, 24, 25, 26, 27, 28, 31, 35, 42, 49, 63, 77, 91, and 119
Absolute Bioavailability of Weekly (x 4) SC Injections of Belimumab
Bioavailability (F) is a measurement of the rate and extent to which a drug reaches the systemic circulation. The bioavailability following weekly (x 4) SC injections of belimumab was calculated by comparing the bioavailability of belimumab administered IV to the bioavailability of belimumab administered via 4 weekly SC injections.
Time frame: Pre-dose, Post-dose on Days 0, 1, 2, 3, 4, 5, 6, 7, 14, 21, 22, 23, 24, 25, 26, 27, 28, 31, 35, 42, 49, 63, 77, 91, and 119
Number of Participants Who Experienced Adverse Events
Includes AEs reported in participants from the first dose of belimumab throughout the study through Day 70/Exit (single dose groups) or Day 119/Exit (multiple dose groups).
Time frame: Up to Day 119
| Milestone | Belimumab IV 240 mg | Belimumab SC 2 x 120 mg | Belimumab SC 1 x 240 mg | Belimumab SC 1 x 200 mg | Belimumab SC 2 x 120 mg Weekly | Belimumab SC 1 x 200 mg Weekly |
|---|---|---|---|---|---|---|
| Started | 19 | 20 | 20 | 19 | 20 | 20 |
| Completed | 19 | 17 | 20 | 18 | 15 | 17 |
| Not completed | 0 | 3 | 0 | 1 | 5 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 3 | 0 | 1 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Lack of compliance | 0 | 0 | 0 | 0 | 1 | 0 |
| days | Belimumab IV 240 mg | Belimumab SC 2 x 120 mg | Belimumab SC 1 x 240 mg | Belimumab SC 1 x 200 mg |
|---|---|---|---|---|
| Time to Reach Maximum Serum Drug Concentration (Tmax) Following a Single Dose of Belimumab Given as Intravenous Infusion (IV) or Subcutaneous Injection (SC) | 0.09 (0.05 to 0.30) | 3.9 (0.9 to 9.8) | 4.9 (2.9 to 13.9) | 5.9 (1.9 to 13.9) |
| days | Belimumab SC 2 x 120 mg Weekly | Belimumab SC 1 x 200 mg Weekly |
|---|---|---|
| Time to Reach Maximum Serum Drug Concentration (Tmax) Following Weekly (x 4) SC Injections of Belimumab | 5.8 ± 1.5 | 5.5 ± 1.2 |
| µg/mL | Belimumab IV 240 mg | Belimumab SC 2 x 120 mg | Belimumab SC 1 x 240 mg | Belimumab SC 1 x 200 mg |
|---|---|---|---|---|
| Maximum Serum Drug Concentration (Cmax) Following a Single Dose of Belimumab Given as IV or SC | 86.2 ± 20.0 | 32.7 ± 29.0 | 31.6 ± 27.9 | 24.3 ± 40.3 |
AUC (0-∞) = Area under the serum drug concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-last) plus C (last)/λz. C (last) is the last measurable concentration. λz was determined by linear regression (r2 ≥ 0.8) with uniform weighting of all data in the terminal linear portion of the log-transformed drug concentration-time profile.
| µg∙day/mL | Belimumab IV 240 mg | Belimumab SC 2 x 120 mg | Belimumab SC 1 x 240 mg | Belimumab SC 1 x 200 mg |
|---|---|---|---|---|
| Area Under the Serum Drug Concentration-time Curve From Time 0 to Infinite Time (AUC0-∞) Following a Single Dose of Belimumab Given as IV or SC | 1030 ± 32.1 | 788 ± 36.1 | 812 ± 36.2 | 612 ± 37.9 |
Terminal elimination half-life is the time measured for the serum drug concentration of belimumab to decrease by one half.
| days | Belimumab IV 240 mg | Belimumab SC 2 x 120 mg | Belimumab SC 1 x 240 mg | Belimumab SC 1 x 200 mg |
|---|---|---|---|---|
| Terminal Elimination Half-life (t1/2,Term) Following a Single Dose of Belimumab Given as IV or SC | 18.2 ± 6.3 | 15.9 ± 5.3 | 18.2 ± 6.0 | 16.0 ± 5.1 |
Bioavailability (F) is a measurement of the rate and extent to which a drug reaches the systemic circulation. The bioavailability of belimumab administered by IV is compared to the bioavailability of belimumab administered via single-SC injection.
| percentage bioavailability | Belimumab IV 240 mg | Belimumab SC 2 x 120 mg | Belimumab SC 1 x 240 mg | Belimumab SC 1 x 200 mg |
|---|---|---|---|---|
| Absolute Bioavailability of a Single Dose of Belimumab Given as IV or SC | NA (NA to NA) | 76.1 (64.5 to 89.9) | 81.8 (70.1 to 95.5) | 73.5 (59.7 to 90.5) |
| µg/mL | Belimumab SC 2 x 120 mg Weekly | Belimumab SC x 1 200 mg Weekly |
|---|---|---|
| Maximum Serum Drug Concentration (Cmax) Following Weekly (x 4) SC Injections of Belimumab | 21.6 ± 23.2 | 19.5 ± 25.1 |
AUC (0-∞) = Area under the serum drug concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-last) plus C (last)/λz. C (last) is the last measurable concentration. λz was determined by linear regression (r2 ≥ 0.8) with uniform weighting of all data in the terminal linear portion of the log-transformed drug concentration-time profile.
| µg∙day/mL | Belimumab SC 2 x 120 mg Weekly | Belimumab SC 1 x 200 mg Weekly |
|---|---|---|
| Area Under the Serum Drug Concentration-time Curve From Time 0 to Infinite Time (AUC0-∞) Following Weekly (x 4) SC Injections of Belimumab | 763 ± 29.8 | 661 ± 31.2 |
Terminal elimination half-life is the time measured for the serum drug concentration of belimumab to decrease by one half.
| days | Belimumab SC 2 x 120 mg Weekly | Belimumab SC 1 x 200 mg Weekly |
|---|---|---|
| Terminal Elimination Half-life (t1/2,Term) Following Weekly (x 4) SC Injections of Belimumab | 20.3 ± 5.2 | 19.8 ± 4.9 |
Bioavailability (F) is a measurement of the rate and extent to which a drug reaches the systemic circulation. The bioavailability following weekly (x 4) SC injections of belimumab was calculated by comparing the bioavailability of belimumab administered IV to the bioavailability of belimumab administered via 4 weekly SC injections.
| percentage bioavailability | Belimumab SC 2 x 120 mg Weekly | Belimumab SC 1 x 200 mg Weekly |
|---|---|---|
| Absolute Bioavailability of Weekly (x 4) SC Injections of Belimumab | 74.7 (62.6 to 89.1) | 77.9 (67.0 to 90.6) |
Includes AEs reported in participants from the first dose of belimumab throughout the study through Day 70/Exit (single dose groups) or Day 119/Exit (multiple dose groups).
| participants | Belimumab IV 240 mg | Belimumab SC 2 x 120 mg | Belimumab SC 1 x 240 mg | Belimumab SC 1 x 200 mg | Belimumab SC 2 x 120 mg Weekly | Belimumab SC 1 x 200 mg Weekly |
|---|---|---|---|---|---|---|
| At least 1 AE | 14 | 11 | 16 | 14 | 18 | 19 |
| At least 1 serious AE | 0 | 0 | 0 | 0 | 1 | 1 |
| An AE resulting in death | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over up to Day 119. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belimumab IV 240 mg | — | 0/19 (0%) | 14/19 (73.7%) |
| Belimumab SC 2 x 120 mg | — | 0/20 (0%) | 11/20 (55%) |
| Belimumab SC 1 x 240 mg | — | 0/20 (0%) | 16/20 (80%) |
| Belimumab SC 1 x 200 mg | — | 0/19 (0%) | 14/19 (73.7%) |
| Belimumab SC 2 x 120 mg Weekly | — | 1/20 (5%) | 17/20 (85%) |
| Belimumab SC 1 x 200 mg Weekly | — | 1/20 (5%) | 19/20 (95%) |
| Event | Belimumab IV 240 mg | Belimumab SC 2 x 120 mg | Belimumab SC 1 x 240 mg | Belimumab SC 1 x 200 mg | Belimumab SC 2 x 120 mg Weekly | Belimumab SC 1 x 200 mg Weekly |
|---|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/19 | 0/20 | 0/20 | 0/19 | 0/20 | 1/20 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/19 | 0/20 | 0/20 | 0/19 | 1/20 | 0/20 |
| Event | Belimumab IV 240 mg | Belimumab SC 2 x 120 mg | Belimumab SC 1 x 240 mg | Belimumab SC 1 x 200 mg | Belimumab SC 2 x 120 mg Weekly | Belimumab SC 1 x 200 mg Weekly |
|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 0/19 | 3/20 | 9/20 | 8/19 | 14/20 | 14/20 |
| HeadacheNervous system disorders | 3/19 | 3/20 | 0/20 | 5/19 | 6/20 | 3/20 |
| ErythemaSkin and subcutaneous tissue disorders | 1/19 | 0/20 | 0/20 | 0/19 | 0/20 | 4/20 |
| Abdominal painGastrointestinal disorders | 3/19 | 0/20 | 0/20 | 0/19 | 0/20 | 0/20 |
| Injection site haemorrhageGeneral disorders | 0/19 | 0/20 | 0/20 | 3/19 | 0/20 | 0/20 |
| DiarrhoeaGastrointestinal disorders | 0/19 | 2/20 | 0/20 | 2/19 | 3/20 | 0/20 |
| Injection site erythemaGeneral disorders | 0/19 | 1/20 | 3/20 | 1/19 | 1/20 | 3/20 |
| Injection site haematomaGeneral disorders | 0/19 | 0/20 | 0/20 | 0/19 | 3/20 | 2/20 |
| Injection site oedemaGeneral disorders | 0/19 | 0/20 | 3/20 | 0/19 | 0/20 | 0/20 |
| Injection site swellingGeneral disorders | 0/19 | 0/20 | 0/20 | 0/19 | 1/20 | 3/20 |
| Age Continuous(years) | Belimumab IV 240 mg | Belimumab SC 2 x 120 mg | Belimumab SC 1 x 240 mg | Belimumab SC 1 x 200 mg | Belimumab SC 2 x 120 mg Weekly | Belimumab SC 1 x 200 mg Weekly | Total |
|---|---|---|---|---|---|---|---|
| Mean | 37.3 ± 12.1 | 33.4 ± 11.4 | 35.2 ± 12.1 | 36.1 ± 9.4 | 33.7 ± 9.5 | 37.4 ± 9.7 | 35.5 ± 10.7 |
| Sex: Female, Male(Participants) | Belimumab IV 240 mg | Belimumab SC 2 x 120 mg | Belimumab SC 1 x 240 mg | Belimumab SC 1 x 200 mg | Belimumab SC 2 x 120 mg Weekly | Belimumab SC 1 x 200 mg Weekly | Total |
|---|---|---|---|---|---|---|---|
| Female | 12 | 13 | 11 | 8 | 11 | 10 | 65 |
| Male | 7 | 7 | 9 | 11 | 9 | 10 | 53 |
| Region of Enrollment(participants) | Belimumab IV 240 mg | Belimumab SC 2 x 120 mg | Belimumab SC 1 x 240 mg | Belimumab SC 1 x 200 mg | Belimumab SC 2 x 120 mg Weekly | Belimumab SC 1 x 200 mg Weekly | Total |
|---|---|---|---|---|---|---|---|
| United States | 19 | 20 | 20 | 19 | 20 | 20 | 118 |
The record gives a start of Feb 2011, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab
Lupus Erythematosus, Systemic →